Robert Conley

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi Comparison of clozapine use in Maryland and in Victoria, Australia
    Robert R Conley
    Maryland Psyciatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Psychiatr Serv 56:320-3. 2005
  2. ncbi Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form
    Robert Conley
    Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Curr Med Res Opin 22:1879-92. 2006
  3. ncbi Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Treatment Research Unit, University of Maryland, Baltimore 21228, USA
    Clin Neuropharmacol 28:163-8. 2005
  4. ncbi The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
  5. ncbi The effects of galantamine on psychopathology in chronic stable schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 32:69-74. 2009
  6. ncbi Plasma concentrations of high-dose olanzapine in a double-blind crossover study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Hum Psychopharmacol 21:393-8. 2006
  7. ncbi The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychopharmacol 18:429-31. 2004
  8. ncbi Cardiovascular disease in relation to weight in deceased persons with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, 21228, USA
    Compr Psychiatry 46:460-7. 2005
  9. ncbi Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore 21228, USA
    J Clin Psychiatry 67:1404-11. 2006
  10. ncbi Synaptic differences in the patch matrix compartments of subjects with schizophrenia: a postmortem ultrastructural study of the striatum
    Rosalinda C Roberts
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Neurobiol Dis 20:324-35. 2005

Research Grants

  1. The Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Weight...
    Robert Buchanan; Fiscal Year: 2007

Detail Information

Publications69

  1. ncbi Comparison of clozapine use in Maryland and in Victoria, Australia
    Robert R Conley
    Maryland Psyciatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Psychiatr Serv 56:320-3. 2005
    ..This study examined the use of clozapine in Maryland and in Victoria, Australia...
  2. ncbi Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form
    Robert Conley
    Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Curr Med Res Opin 22:1879-92. 2006
    ..The osmotic-controlled release oral delivery system, OROS, is an advanced drug delivery technology that uses osmotic pressure as the driving force to deliver pharmacotherapy, usually once-daily, in several therapeutic areas...
  3. ncbi Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Treatment Research Unit, University of Maryland, Baltimore 21228, USA
    Clin Neuropharmacol 28:163-8. 2005
    ..Treatment with first- and second-generation antipsychotics may demonstrate similar efficacy; however, patients treated with second-generation antipsychotics may be more likely to adhere to treatment...
  4. ncbi The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
    ..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...
  5. ncbi The effects of galantamine on psychopathology in chronic stable schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 32:69-74. 2009
    ..This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia...
  6. ncbi Plasma concentrations of high-dose olanzapine in a double-blind crossover study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Hum Psychopharmacol 21:393-8. 2006
    ..In conclusion, this study reports plasma olanzapine levels at high fixed doses of olanzapine (50 mg/day) in relation to side effects, symptoms, smoking, and gender...
  7. ncbi The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychopharmacol 18:429-31. 2004
    ..These findings suggest that high doses of olanzapine do not produce similar brain activation patterns as clozapine in people with treatment-resistant schizophrenia...
  8. ncbi Cardiovascular disease in relation to weight in deceased persons with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, 21228, USA
    Compr Psychiatry 46:460-7. 2005
    ....
  9. ncbi Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore 21228, USA
    J Clin Psychiatry 67:1404-11. 2006
    ..This study extends previous studies of clozapine by examining patient- and treatment-related factors that may help explain or eliminate reasons for differential prescribing...
  10. ncbi Synaptic differences in the patch matrix compartments of subjects with schizophrenia: a postmortem ultrastructural study of the striatum
    Rosalinda C Roberts
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Neurobiol Dis 20:324-35. 2005
    ..These changes appeared to be normalized rather than caused by treatment. The abnormal connectivity may represent a failure of normal synaptic pruning and may play a role in limbic or cognitive dysfunction in schizophrenia...
  11. ncbi A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, 21228, USA
    Psychoneuroendocrinology 31:340-6. 2006
    ..Overall, quetiapine was associated with a normalization of prolactin levels and had the greatest benefits among these drugs regarding sexual functioning...
  12. ncbi Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychiatr Res 38:531-6. 2004
    ..Individuals who die by suicide experience higher rates of depressive symptoms, suicidal thoughts and positive symptoms during their life...
  13. ncbi More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore MD, USA
    Stat Med 24:11-21. 2005
    ....
  14. ncbi Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine
    Deanna L Kelly
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 66:80-4. 2005
    ..Furthermore, the need for thyroid function monitoring in patients taking this medication is not definitive...
  15. ncbi Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD 21228, USA
    Psychiatr Q 77:81-95. 2006
    ..The addition of divalproex was significantly more effective in reducing global symptoms (driven by hostility and anxiety) in the first month of adjunct treatment as compared to clozapine monotherapy and to previous clozapine treatment...
  16. ncbi Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis
    Rosalinda C Roberts
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Synapse 56:185-97. 2005
    ..The abnormal synaptic organization could have several important and different downstream effects depending on the precise circuitry involved and may be related to limbic or cognitive dysfunction in schizophrenia...
  17. ncbi First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
    ....
  18. ncbi Sexuality and schizophrenia: a review
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 30:767-79. 2004
    ..Treatment options and psychosocial issues pertaining to sexuality also are presented...
  19. ncbi Atypical antipsychotic use in a state hospital inpatient adolescent population
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, USA
    J Child Adolesc Psychopharmacol 14:75-85. 2004
    ..More research is needed to develop useful and specific practice guidelines in children and adolescents for these commonly used medications...
  20. ncbi Clozapine underutilization and discontinuation in African Americans due to leucopenia
    Deanna L Kelly
    The Maryland Psychiatric Research Center, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 33:1221-4. 2007
    ....
  21. ncbi Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
    ..High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine...
  22. ncbi Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials
    Robert P McMahon
    Department of Psychiatry, Maryland Psychiatric Research Center, Spring Grove Hospital Grounds, Maple and Locust Avenues, PO Box 21247, Baltimore, MD 21228, USA
    Neuropsychopharmacology 26:537-45. 2002
    ..We recommend these four factor scores as clinical trial outcomes in patients with treatment resistant schizophrenia...
  23. ncbi A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 70:518-25. 2009
    ..In animals, it has been shown to increase extracellular levels of acetylcholine and dopamine in cortical and hippocampal regions...
  24. ncbi Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis
    William T Regenold
    Division of Geriatric Psychiatry, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Biol Psychiatry 65:489-94. 2009
    ..We tested the hypothesis that patients with bipolar disorder and schizophrenia would, on average, have elevated CSF lactate concentrations compared with healthy control subjects...
  25. ncbi Clozapine treatment in patients with prior substance abuse
    Deanna L Kelly
    School of Medicine, University of Maryland, Baltimore, Maryland, USA
    Can J Psychiatry 48:111-4. 2003
    ..This study examined outcomes following discharge on clozapine for treatment-resistant schizophrenia patients with and without diagnosed substance abuse histories...
  26. ncbi Current status of antipsychotic treatment
    Robert R Conley
    University of Maryland, Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Curr Drug Targets CNS Neurol Disord 1:123-8. 2002
    ..Optimization of treatment and understanding the exact mechanism of action of current antipsychotic medications will help pave the way for new drug targets in the future...
  27. ncbi Rehospitalization risk with second-generation and depot antipsychotics
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:23-31. 2003
    ..SGAs may provide better long-term prognoses and outcomes for patients with schizophrenia...
  28. ncbi Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients
    William T Regenold
    Department of Psychiatry, Division of Geriatric Psychiatry, University of Maryland School of Medicine, Baltimore, MD
    Bipolar Disord 10:753-64. 2008
    ..This study investigated whether brain glucose metabolism by the polyol pathway--a pathway linked to nervous tissue disease in diabetes--is related to deep WMH volume and treatment resistance in BD patients...
  29. ncbi Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 22147 Baltimore, MD 21228, United States
    Schizophr Res 103:161-8. 2008
    ..53, df=1, p=0.019), for an effect size of 0.4. These results suggest that galantamine has no effect on cigarette smoking and that during galantamine treatment nicotine dependency scores worsen...
  30. ncbi Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 20:71-8. 2008
    ..This study examined weight and metabolic changes with two widely used antipsychotics, risperidone and olanzapine; addressing the issue of early monitoring for metabolic side effects...
  31. ncbi Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia
    Ikwunga Wonodi
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, 21228, USA
    Am J Med Genet B Neuropsychiatr Genet 150:282-9. 2009
    ..05), but higher expression in schizophrenia donors. Findings suggest regulatory effects of another gene(s) or etiological factor in schizophrenia, which modulate DAT1 gene function...
  32. ncbi Comparison of clozapine response for inpatients in the research setting versus routine clinical practice
    Douglas L Boggs
    Maryland Psychiatric Research Center, School of Medicine, University of Maryland Baltimore, Baltimore, MD 21228, USA
    Psychiatr Q 79:111-9. 2008
    ..This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment...
  33. ncbi Galantamine for the treatment of cognitive impairments in people with schizophrenia
    Robert W Buchanan
    Department of Psychiatry, University of Maryland, Baltimore, MD, USA
    Am J Psychiatry 165:82-9. 2008
    ....
  34. ncbi Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone
    Matthew W Nelson
    VA Capitol Healthcare Network Mental Illness Research Education and Clinical Care Center MIRECC, Veterans Affairs, Maryland Health Care System, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 26:297-8. 2003
    ..Controlled trials of quetiapine in the treatment of tardive dyskinesia should be pursued...
  35. ncbi Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Compr Psychiatry 51:298-302. 2010
    ....
  36. ncbi Reaching for wellness in schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Clin North Am 30:453-79. 2007
    ..Although treatment of risk factors for CHD is still far from ideal, all attempts should be made to strive for wellness to improve patients' long-term outcomes...
  37. ncbi Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients
    Robert R Conley
    Maryland Psychiatric Research Center in the University of Maryland School of Medicine at Baltimore, MD 21228, USA
    Psychopharmacol Bull 40:77-97. 2007
    ..This review will assess the clinical relevance of these interactions for physicians and patients with schizophrenia...
  38. ncbi Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 21247, Baltimore, MD 21228, USA
    J Clin Psychiatry 71:304-11. 2010
    ..Cardiovascular disease (CVD) mortality in schizophrenia is more frequent than in the general population. Whether second-generation antipsychotics (SGAs) increase risk of CVD morbidity and mortality has yet to be determined...
  39. ncbi The heterogeneity of schizophrenia in disease states
    Penny E Mohr
    Centers for Medicare and Medicaid Services, ORDI REG DBR, Mail stop C3 19 07 7500, Security Boulevard, Baltimore, MD 21244, USA
    Schizophr Res 71:83-95. 2004
    ....
  40. ncbi Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland, USA
    Isr J Psychiatry Relat Sci 42:51-60. 2005
    ..Because certain side effects may be associated with nonadherence with treatment, more detailed data for each of the SGA with regards to EPS, weight gain and metabolic abnormalities and sexual dysfunction are presented...
  41. ncbi Circumstances of suicide among individuals with schizophrenia
    Julie A Kreyenbuhl
    Maryland Psychiatric Research Center, University of Maryland, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 58:253-61. 2002
    ..Suicide in schizophrenia is a significant clinical problem; thus, prior suicidal activity and depressive symptoms should be addressed because opportunities to intervene immediately before the act are limited...
  42. ncbi Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia
    Brian Kirkpatrick
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
    J Nerv Ment Dis 191:563-7. 2003
    ..27 (.10),.53 (.39), and.76 (.20) cells per 10-6 cubic microns. These group differences provide further evidence that deficit and nondeficit schizophrenia differ in their pathophysiology...
  43. ncbi Challenge to atypical antipsychotic drug effect on cognition
    William T Carpenter
    Am J Psychiatry 164:1910-1; author reply 1911-2. 2007
  44. ncbi Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine
    Deanna L Kelly
    J Clin Psychiatry 64:1133-4. 2003
  45. ncbi Quetiapine at high doses for the treatment of refractory schizophrenia
    Douglas L Boggs
    Schizophr Res 101:347-8. 2008
  46. ncbi Postmortem brain tissue of depressed suicides reveals increased Gs alpha localization in lipid raft domains where it is less likely to activate adenylyl cyclase
    Robert J Donati
    Department of Physiology and, University of Illinois at Chicago, College of Medicine, Chicago, Illinois 60612 7342, USA
    J Neurosci 28:3042-50. 2008
    ..Raft localization of Gs alpha in human peripheral tissue may thus serve as a biomarker for depression and as a harbinger of antidepressant responsiveness...
  47. ncbi Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia
    Rosalinda C Roberts
    Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Synapse 62:616-27. 2008
    ..The selective increase in axospinous synapses in the matrix of the SZU subgroup compared to the SZP may be related to more severe cognitive problems in that subset of SZ compared to SZP...
  48. ncbi Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects
    Yogesh Dwivedi
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 60612, USA
    Arch Gen Psychiatry 60:804-15. 2003
    ....
  49. ncbi The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia
    Do-Un Jung
    J Clin Psychopharmacol 25:613-5. 2005
  50. ncbi The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study
    Robert R Conley
    J Clin Psychopharmacol 23:668-71. 2003
  51. ncbi Fluoxetine augmentation of haloperidol in chronic schizophrenia
    Joo-Cheol Shim
    J Clin Psychopharmacol 23:520-2. 2003
  52. ncbi Evaluating sexual function in patients with treatment-resistant schizophrenia
    Deanna L Kelly
    Schizophr Res 63:195-6. 2003
  53. ncbi Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics
    Samuel J Keith
    J Clin Psychiatry 65:120-31. 2004
  54. ncbi The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update
    Troy A Moore
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
    J Clin Psychiatry 68:1751-62. 2007
    ....
  55. ncbi Deaths from diabetic ketoacidosis after long-term clozapine treatment
    Heidi J Wehring
    Am J Psychiatry 160:2241-2. 2003
  56. ncbi Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia
    Joo-Cheol Shim
    Department of Psychiatry, Inje University, Busan, Korea
    J Neuropsychiatry Clin Neurosci 17:221-6. 2005
    ..This finding suggests that decreased dopamine (D(2)) receptor sensitivity may result in lower risk of developing TD and may lead to a fuller understanding of the variable expression of D(2)-receptor mediated side effects...
  57. ncbi Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study
    William M Glazer
    Glazer Medical Solutions, Menemsha, MA, USA
    CNS Spectr 11:1-13; quiz 14. 2006
    ....
  58. ncbi Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus
    Ghanshyam N Pandey
    The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA
    Int J Neuropsychopharmacol 10:621-9. 2007
    ....
  59. ncbi Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study
    Do-Un Jung
    Department of Psychiatry, Dongseo Hospital, Masan, Republic of Korea
    J Clin Psychiatry 67:1391-6. 2006
    ..CONCLUSIONS: Bone mineral density loss in patients with schizophrenia tended to differ by gender. Decreased BMD compared to normal controls was seen in female patients; however, this was not observed in men...
  60. ncbi Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims
    Ghanshyam N Pandey
    Department of Psychiatry, The Psychiatric Institute, University of Illinois at Chicago, Chicago, IL 60612, USA
    Neuropsychopharmacology 30:1548-56. 2005
    ..Whether these changes in PKA subunits are related to suicidal behavior or are a result of suicide or are specific to suicide is not clear at this point...
  61. ncbi The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004
    ..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
  62. ncbi Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis
    Joo Cheol Shim
    J Clin Psychopharmacol 27:400-1. 2007
  63. ncbi Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis
    Tim Lambert
    J Clin Psychopharmacol 24:91-3. 2004
  64. ncbi Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial
    Joo Cheol Shim
    Clinical Trial Center, Department of Psychiatry and Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan 614 735, Republic of Korea
    Am J Psychiatry 164:1404-10. 2007
    ..The authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and psychopathology in patients with schizophrenia maintained with haloperidol...
  65. ncbi Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits
    Yogesh Dwivedi
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, IL 60612, USA
    Biol Psychiatry 55:234-43. 2004
    ..Here we examined the molecular basis of these alterations and whether these findings can be replicated in another cohort...
  66. ncbi Suicide brain is associated with decreased expression of neurotrophins
    Yogesh Dwivedi
    Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Biol Psychiatry 58:315-24. 2005
    ..Neurotrophins mediate diverse biological responses, including maintenance and growth of neurons and synaptic plasticity in adult brain. This study examined whether suicide brain is associated with changes in the expression of neurotrophins...
  67. ncbi Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects
    Yogesh Dwivedi
    Department of Psychiatry, Psychiatric Institute, University of Illinois at Chicago, Chicago, IL 60612, USA
    Neuropsychopharmacology 32:2338-50. 2007
    ....
  68. ncbi Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims
    Ghanshyam N Pandey
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 60612, USA
    Am J Psychiatry 159:419-29. 2002
    ..The authors examined whether 5-HT(2A) receptor subtypes are altered in the postmortem brains of teenage suicide victims...
  69. ncbi mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims
    Yogesh Dwivedi
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor Street, 60612, USA
    Neuropsychopharmacology 27:499-517. 2002
    ..Our results suggest that there are defects in the expression of selective G protein alpha subunits in prefrontal cortex of adult and teenage suicide subjects, which appear to be related to mental disorders...

Research Grants1

  1. The Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Weight...
    Robert Buchanan; Fiscal Year: 2007
    ..There should be direct evidence of efficacy and safety in these patients in order to provide truly effective treatments and further understanding of these disorders. ..